ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Early assessment of the impact of mitigation measures to control COVID-19 in 22 French metropolitan areas, October to November 2020.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Social inequalities in COVID-19-related years of life lost in metropolitan France, 2020.Archives of public health = Archives belges de sante publique · 2025Article
- The changing pattern of common respiratory viruses among children from 2018 to 2021 in Wuhan, China.Archives of virology · 2023Article
- Direct impact of COVID-19 by estimating disability-adjusted life years at national level in France in 2020.PloS one · 2023Article
- Article
- Impact of COVID-19 epidemic on antihypertensive drug treatment disruptions: results from a nationwide interrupted time-series analysis.Frontiers in pharmacology · 2023Article
- COVID-19 vaccine intention among young adults: Comparative results from a cross-sectional study in Canada and France.Vaccine · 2022Article
- Evolution of baseline characteristics and severe outcomes in COVID-19 inpatients during the first and second waves in Northeastern France.Infectious diseases now · 2022Article
- Article
- COVID-19 hotspots through clusters analysis in France (may-October 2020): where should we track the virus to mitigate the spread?BMC public health · 2021Article
- Can shellfish be used to monitor SARS-CoV-2 in the coastal environment?The Science of the total environment · 2021Article
- Impact of January 2021 curfew measures on SARS-CoV-2 B.1.1.7 circulation in France.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2021Article
- Viral RNA in City Wastewater as a Key Indicator of COVID-19 Recrudescence and Containment Measures Effectiveness.Frontiers in microbiology · 2021Article
- Characteristic and outcome changes in inpatients with COVID-19 during the four pre - Omicron waves.HippokratiaArticle
- Out-of-hospital mortality as an indicator of health care system saturation: Two waves retrospective analysis.Travel medicine and infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In France, measures including curfew and lockdown were implemented to control the COVID-19 pandemic second wave in 2020. This study descriptively assesses their possible effects, also relative to their timing. A considerable decrease in incidence of COVID-19 cases and hospital admissions was observed 7 to 10 days after mitigation measures were put in place, occurring earlier in metropolitan areas which had implemented these first. This temporal coincidence suggests the measures' positive impact, consistent with international experiences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.